Ocugen CEO Will Speak at Phoenix Biotech Conference
The executive will join a panel discussion at the upcoming Cell & Gene Meeting on the Mesa in Phoenix on October 6.
Updated on Oct. 4, 2026 in Biotech
Live Poll
Do you trust that new medical gene therapies will be effectively commercialized for broad patient use?
Ocugen CEO Shankar Musunuri is scheduled to participate in a panel session at the Cell & Gene Meeting on the Mesa 2026. The event, which takes place in Phoenix on October 6, 2026, will feature discussions on regulatory approval and the commercialization of new therapies.
Why it matters
The company seeks to broaden its impact on patients by developing modifier gene therapies that address multiple gene networks rather than individual mutations. This approach targets a larger patient population than traditional mutation-specific treatments.
The firm utilizes a gene-agnostic approach to influence multiple gene networks involved in retinal disease biology. Its current pipeline includes active programs for retinitis pigmentosa, Stargardt disease, and geographic atrophy.
The players
Shankar Musunuri
He is the CEO of Ocugen and oversees the company's research into gene-agnostic retinal therapies.
Ocugen
This biotechnology firm, headquartered in Malvern, Pennsylvania, develops modifier gene therapies for inherited retinal diseases.
The details
Ocugen, based in Malvern, Pennsylvania, trades on the NASDAQ as OCGN and specializes in therapies for inherited retinal diseases. During the panel, the CEO will focus on the path toward regulatory approval for their developing gene therapy programs.
Timeline
The panel session is scheduled for October 6, 2026, from 2:15 p.m. to 3:15 p.m. MST.
The Tech Race
The development of modifier gene therapies represents a shift away from traditional approaches that focus on singular genetic mutations. This positions the firm as a competitor to entities focusing on narrow-scope orphan drug treatments for retinal blindness.
For patients and investors, the discussion on regulatory milestones provides insight into the potential commercialization timeline for new retinal treatments. These updates help stakeholders gauge when these gene therapies might move from development to clinical availability.
The takeaway
Modifier gene therapies offer a promising path for addressing complex inherited retinal diseases by targeting entire networks of genetic activity. This strategy aims to provide more scalable treatment solutions for patients who do not qualify for therapies designed for specific mutations.
Further reading
Learn more about the latest industry trends by visiting Biotech.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust that new medical gene therapies will be effectively commercialized for broad patient use?
